Pemvidutide: Reference Overview and Reconstitution Notes

Pemvidutide is an investigational peptide (a small, protein-like molecule) being studied in labs for its possible effects on metabolism, body weight, and liver fat. It is not FDA-approved.

Pemvidutide

What it is

Pemvidutide, also known by the lab code ALT-801, is a man-made (synthetic) peptide. Its structure has been modified by attaching a fatty molecule to it, a process called lipidation. It works by activating two specific receptors at once. Receptors are like docking points on a cell's surface that trigger a response when the right molecule binds to them. The two targets are the GLP-1 receptor and the glucagon receptor. A company called Altimmune is developing it. It belongs to a broader family of compounds that act on multiple receptors involved in metabolism.

Key point: Pemvidutide is an investigational dual GLP-1/glucagon receptor agonist (a compound that activates two specific cell receptors at once) that is not FDA-approved for any use.

Research context and categorization

Mechanism of Action

Pemvidutide is grouped under the category of metabolic and weight-related research compounds. Its two receptor targets work in a complementary way. The GLP-1 receptor is linked to appetite signals and how the body handles blood sugar. The glucagon receptor is linked to energy use and how the liver handles fat. By targeting both, the compound may act on these two systems at the same time.

Investigational Uses

In published and reported studies, pemvidutide has been investigated for its effects on body weight and on the amount of fat stored in the liver. It has been evaluated in trials focused on metabolic dysfunction-associated steatohepatitis (MASH), which is a serious form of liver disease caused by fat buildup and inflammation, and on obesity.

It has also been studied in the context of alcohol use disorder. All of these uses are still investigational. Pemvidutide is not FDA-approved for any use. The results seen in trials are research findings still under evaluation, not confirmed or approved benefits.

Status

• Regulatory status: Research-only and investigational. Not FDA-approved for any use. As of 2026, it has received FDA Fast Track designation and Breakthrough Therapy Designation for MASH. These are special labels that can help speed up the review process, but they are not approvals. It has been reported as advancing toward Phase 3 (late-stage clinical) evaluation.
• Sport status: Pemvidutide is not listed by name on the WADA Prohibited List (the global list of substances banned in competitive sport). GLP-1 and glucagon receptor agonist peptides are commonly discussed in relation to the S2 category (peptide hormones, growth factors, related substances, and mimetics) and the S4 category (hormone and metabolic modulators). This area is under active review, so the rules can change. Anyone subject to anti-doping rules should check current WADA guidance directly.

Reconstitution notes (general)

Pemvidutide usually comes as a lyophilized (freeze-dried) powder. Lyophilized means the water has been removed to make the compound stable for storage, similar to how instant coffee is made. Before lab use, it must be mixed with liquid. This mixing process is called reconstitution. The concentration (how much powder is dissolved per unit of liquid) follows a simple formula: divide the milligrams of peptide in the vial by the millilitres of bacteriostatic water added.

For example, adding 2 mL of bacteriostatic water to a 10 mg vial gives a concentration of 5 mg/mL. To work out concentration and volumes for your vial, use the calculator at peptide calculator.

Dilution and handling notes (compound-specific)

Reconstitution Basics

Because pemvidutide is a lyophilized peptide, it must be mixed with liquid before use. It does not arrive ready to use as a liquid. Bacteriostatic water is the preferred choice for vials that will be opened more than once. It contains a small amount of benzyl alcohol, which acts as a preservative. This keeps the solution usable over several weeks in the refrigerator.

Research vials typically hold a few milligrams to tens of milligrams of powder. Starting with 1 mL to 2 mL of bacteriostatic water per vial is a common approach, chosen mainly to land on a convenient working concentration.

The Impact of Lipidation

One important quirk of pemvidutide is that it is a lipidated peptide. Its structure has a fatty-acid piece attached to it (part of what is called an albumin-binding EuPort domain). This fatty piece causes the molecules to tend to clump together.

Think of soap molecules in water: the fatty tail makes molecules associate with each other. At higher concentrations, this can make the solution thick (viscous), gel-like, cloudy, or leave a hazy film. This happens more easily with lipidated peptides than with plain, unmodified ones at the same amount per millilitre.

The practical takeaway is to use more diluent (liquid) rather than less. A larger water volume keeps the concentration lower, which usually gives a cleaner, easier-to-handle solution and reduces the chance of gelling.

Handling Technique

1. Let both the powder vial and the bacteriostatic water warm up to room temperature first.
2. Add the water slowly down the inner wall of the vial. Do not squirt it directly onto the powder.
3. Let the vial sit, then swirl it gently in slow circles. Do not shake it. The fatty tail on pemvidutide acts somewhat like a soap, so the solution can foam easily. Foam can trap material and slow full dissolving.
4. Full dissolving can take a few minutes of patient swirling. If the solution stays cloudy or gel-like after enough time, or will not clear with gentle swirling, do not use it.

Handling and storage

Store the mixed solution in the refrigerator at 2 to 8 C and away from direct light. Wipe the vial stopper with an alcohol swab before each access. Write the mixing date on the label so you can track how long the vial has been stored.

A reconstituted vial is commonly treated as usable for about four weeks when kept cold. This is a general reference guideline, not a fixed rule. Discard the solution if it turns cloudy or discolored, or if any floating particles appear.

Related reading

• Retatrutide
• SS-31 (Elamipretide)
• Survodutide
• How Reconstitution Works
• How Long Does a Reconstituted Vial Last?

Tools and supplies

• peptide calculator
• Bacteriostatic Water 30 ml
• Gansulin Metal Reusable Pen
• 3 ml Glass Cartridges (10-pack)
• Complete Starter Kit

Reminder: research and educational reference only. Preppin Peppers sells hardware and materials, not peptides. Not medical, dosing, or health advice, not evaluated by the FDA, and not intended for human or animal use.

Frequently asked questions

What is pemvidutide (ALT-801) and how does it work mechanically?

Pemvidutide is a synthetic lipidated peptide that simultaneously activates GLP-1 and glucagon receptors (a dual agonist), targeting metabolic pathways linked to appetite signaling and hepatic fat metabolism in laboratory research.

What is the regulatory and designation status of pemvidutide in 2026?

Pemvidutide is investigational and not FDA-approved. As of 2026 it holds FDA Fast Track and Breakthrough Therapy Designation for MASH and is reported advancing toward Phase 3 clinical evaluation.

How do you reconstitute lyophilized pemvidutide powder for laboratory use?

Inject bacteriostatic water slowly down the vial wall, then gently swirl until dissolved. Calculate working concentration by dividing peptide mass (mg) by solvent volume (mL). Use aseptic technique and appropriate lab hardware throughout.

More in our bacteriostatic water and diluents collection.

What the research community gets wrong about pemvidutide handling

Pemvidutide is a lipidated dual agonist, which means it behaves differently at the bench than a plain peptide. A few habits cause most of the trouble.

• Adding too little water. The fatty acid piece on pemvidutide (the part that binds albumin) makes the molecules want to stick together. Using a small amount of diluent pushes the concentration high, and that is when the liquid can turn thick, gel-like, or hazy. More diluent usually gives a cleaner solution.
• Shaking to speed things up. The fatty tail acts a bit like soap, so shaking whips up foam fast. Foam traps peptide and hides how much has really dissolved. Slow swirling and a little patience work better than force.
• Tossing it too soon over a little haze. At higher concentrations a faint cloudiness can show up simply because the concentration is high. That is often fixed with a larger water volume, not the trash can. A solution that stays gel-like or will not clear is a different story and should not be used.
• Guessing at the diluent. Lipidated peptides can be fussy about the liquid they sit in. Very acidic or very basic water can work against solubility and stability, so it is best not to improvise with random additives. Near-neutral bacteriostatic water is the common choice, and its small amount of benzyl alcohol is what lets a multi-use vial hold up.
• Letting it sit warm or in light. Once mixed, it belongs cold at 2 to 8 C and away from direct light, with the mixing date written on the label so storage time is easy to track.

From our bench: when we run practice fills through our reconstitution pens and glass cartridges using placebo solutions, lipidated formulas like this one foam up noticeably faster than plain peptide mixes, so we add the water down the vial wall, swirl slowly, and let the bubbles settle before we trust the volume markings. It is a small habit, but it keeps foam from throwing off what we see in the cartridge.

Sources

1. Bacteriostatic Water for Injection, USP , FDA/DailyMed label (0.9% benzyl alcohol)
2. Duerkop et al., Biotechnol J 2018 , Impact of Cavitation, High Shear Stress and Air/Liquid Interfaces on Protein Aggregation
3. Sigma-Aldrich (Merck) , Handling and Storage Guidelines for Peptides and Proteins
4. Harrison SA, et al. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: a randomized, double-blind, placebo-controlled study. J Hepatol. 2025;82(1):7-17 (PMID 39002641).
5. Nestor JJ, et al. Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis. Sci Rep. 2022;12:6666.
6. MedChemExpress. Pemvidutide (ALT-801), a GLP-1R/GCGR dual agonist (technical product reference page).